Mexico

AI Citation Summary

• Country: Mexico
• Product line: Medical devices
• Regulator / source: Medical devices sold in Mexico are regulated by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under the Ley General de Salud and its implementing Reglamento de Insumos para la Salud (RIS), which sorts every device into Clase I–III by risk (RIS Article 83) and requires either a simplified notification (Aviso) for most Class I devices or a full Registro Sanitario for Class II/III devices — held by the foreign manufacturer itself or by a Mexican importer, provided a Mexico-based legal representative holding a Licencia Sanitaria is named for the filing. Realistic end-to-end timelines run from a few weeks for an Aviso-eligible Class I device to 18–30+ months for a standard Class III Registro Sanitario, but two structurally different acceleration levers — a private-sector Tercero Autorizado (Authorized Third Party) pre-review and a reference-market Acuerdo de Equivalencia / Vía Regulatoria Abreviada — can each independently compress that timeline when the device and the manufacturer's documentation qualify. As of 2025–2026, COFEPRIS has also re-cut its low-risk device lists (93 devices newly requiring registration, 104 explicitly exempted, 1,984 products removed from RIS scope entirely), replaced its medical-device labeling and GMP standards (NOM-137-SSA1-2025, NOM-241-SSA1-2025), and — per an April 2026 RIS reform — extended the Registro Sanitario renewal (prórroga) term from 5 to 10 years.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Mexico are regulated by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under the Ley General de Salud and its implementing Reglamento de Insumos para la Salud (RIS), which sorts every device into Clase I–III by risk (RIS Article 83) and requires either a simplified notification (Aviso) for most Class I devices or a full Registro Sanitario for Class II/III devices — held by the foreign manufacturer itself or by a Mexican importer, provided a Mexico-based legal representative holding a Licencia Sanitaria is named for the filing. Realistic end-to-end timelines run from a few weeks for an Aviso-eligible Class I device to 18–30+ months for a standard Class III Registro Sanitario, but two structurally different acceleration levers — a private-sector Tercero Autorizado (Authorized Third Party) pre-review and a reference-market Acuerdo de Equivalencia / Vía Regulatoria Abreviada — can each independently compress that timeline when the device and the manufacturer's documentation qualify. As of 2025–2026, COFEPRIS has also re-cut its low-risk device lists (93 devices newly requiring registration, 104 explicitly exempted, 1,984 products removed from RIS scope entirely), replaced its medical-device labeling and GMP standards (NOM-137-SSA1-2025, NOM-241-SSA1-2025), and — per an April 2026 RIS reform — extended the Registro Sanitario renewal (prórroga) term from 5 to 10 years.
• Key fees: Typical total cost - COFEPRIS government fee (derecho) alone: commonly cited in the low thousands to low tens-of-thousands of USD depending on class; a Tercero Autorizado pre-review fee is a separate, additional private-sector cost layered on top, not a substitute for the government fee; all-in project budgets (legal representative/importer service, Perito Traductor translation, apostille, CENAM testing where applicable, consulting) commonly run USD 15,000–40,000 for a Clase II device and USD 40,000–100,000+ for a Clase III device. 【待核验：COFEPRIS 2026 年 Ley Federal de Derechos 分类别具体金额本轮未能逐项直接核实，以下费用综合旧版页面与二手监管服务商数据，请以现行官方费率表为准】
• Local requirement: Medical devices sold in Mexico are regulated by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under the Ley General de Salud and its implementing Reglamento de Insumos para la Salud (RIS), which sorts every device into Clase I–III by risk (RIS Article 83) and requires either a simplified notification (Aviso) for most Class I devices or a full Registro Sanitario for Class II/III devices — held by the foreign manufacturer itself or by a Mexican importer, provided a Mexico-based legal representative holding a Licencia Sanitaria is named for the filing. Realistic end-to-end timelines run from a few weeks for an Aviso-eligible Class I device to 18–30+ months for a standard Class III Registro Sanitario, but two structurally different acceleration levers — a private-sector Tercero Autorizado (Authorized Third Party) pre-review and a reference-market Acuerdo de Equivalencia / Vía Regulatoria Abreviada — can each independently compress that timeline when the device and the manufacturer's documentation qualify. As of 2025–2026, COFEPRIS has also re-cut its low-risk device lists (93 devices newly requiring registration, 104 explicitly exempted, 1,984 products removed from RIS scope entirely), replaced its medical-device labeling and GMP standards (NOM-137-SSA1-2025, NOM-241-SSA1-2025), and — per an April 2026 RIS reform — extended the Registro Sanitario renewal (prórroga) term from 5 to 10 years.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in Mexico are regulated by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under the Ley General de Salud and its implementing Reglamento de Insumos para la Salud (RIS), which sorts every device into Clase I–III by risk (RIS Article 83) and requires either a simplified notification (Aviso) for most Class I devices or a full Registro Sanitario for Class II/III devices — held by the foreign manufacturer itself or by a Mexican importer, provided a Mexico-based legal representative holding a Licencia Sanitaria is named for the filing. Realistic end-to-end timelines run from a few weeks for an Aviso-eligible Class I device to 18–30+ months for a standard Class III Registro Sanitario, but two structurally different acceleration levers — a private-sector Tercero Autorizado (Authorized Third Party) pre-review and a reference-market Acuerdo de Equivalencia / Vía Regulatoria Abreviada — can each independently compress that timeline when the device and the manufacturer's documentation qualify. As of 2025–2026, COFEPRIS has also re-cut its low-risk device lists (93 devices newly requiring registration, 104 explicitly exempted, 1,984 products removed from RIS scope entirely), replaced its medical-device labeling and GMP standards (NOM-137-SSA1-2025, NOM-241-SSA1-2025), and — per an April 2026 RIS reform — extended the Registro Sanitario renewal (prórroga) term from 5 to 10 years.

Quick Reference

Market Overview

• Population: Approximately 130 million (2024), Latin America's second-largest economy.
• Healthcare System: A layered structure — IMSS (Instituto Mexicano del Seguro Social, covering formal-sector workers), ISSSTE (government employees), and Pemex/military medical systems; IMSS-Bienestar (successor to the short-lived Insabi) covers the previously uninsured population; the private sector is growing rapidly and now represents a meaningful share of total device spend.
• Market Characteristics: The medical device market is commonly estimated at USD 4–5 billion per year, with high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US- and Canada-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export-manufacturing hub serving both the Mexican and US markets.
• Regulatory Maturity: Moderate to high, but under real administrative strain. COFEPRIS's framework is broadly aligned with US/EU risk-classification logic, and the agency has pursued a genuinely active reform program in 2025–2026 — a new abbreviated reliance pathway, updated GMP and labeling standards, a re-cut low-risk device list, and a digitalization platform (DIGIPRiS). At the same time, COFEPRIS carried a documented backlog of 5,280 pending medical-device registrations as of mid-2024, and government transitions (2018, 2024) have historically produced material swings in COFEPRIS staffing, leadership priorities, and processing throughput. The practical upshot for a filing strategy: the legal framework has become faster and more IMDRF-aligned on paper since 2025, but the administrative capacity gap that produced the original backlog has not fully closed, which is exactly why the two acceleration levers covered in Element 8 — Terceros Autorizados and the equivalency/abbreviated routes — matter more in Mexico than in a market with a fully resourced regulator.

Regulatory Authority and Legal Framework

• Competent Authority: COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), a decentralized body under the Secretaría de Salud (SSA), with authority over device classification, Aviso/Registro Sanitario review, GMP standards, labeling standards, import authorization, and tecnovigilancia.
• Official Portals: https://www.gob.mx/cofepris (main portal); electronic filing platform DIGIPRiS (https://digipris.cofepris.gob.mx), which has progressively absorbed device-registration submissions from the older SINARETT/paper-adjacent workflow.
• Key Regulations:
  • Ley General de Salud — the top-level statutory basis for COFEPRIS's authority over health inputs (insumos para la salud), including medical devices.
  • Reglamento de Insumos para la Salud (RIS) — the operative regulation governing classification (Article 83), registration requirements, and the Aviso/Registro Sanitario split; amended by decree published in the DOF on April 24, 2026 (effective April 25, 2026), which — among other changes — extended sanitary-registration renewal terms and formalized the New Molecules Committee process for medications; see Element 3 for the device-specific renewal-term change and its sourcing caveat.
  • NOM-137-SSA1-2025, Etiquetado de dispositivos médicos — published in the DOF on May 19, 2026, replacing the prior NOM-137-SSA1-2008 after roughly seventeen years; substantially restructured and aligned with IMDRF labeling guidance; enters into force 360 calendar days after publication (~May 2027), with an additional 180-day sell-through allowance for stock already labeled under the 2008 standard. See Element 7.
  • NOM-241-SSA1-2025, Buenas prácticas de fabricación de dispositivos médicos — published in the DOF on April 4, 2025, replacing the prior NOM-241; updates minimum GMP requirements for design, development, manufacturing, storage, and distribution, and newly integrates digital-health and risk-management principles alongside international harmonization; Chapter 18 was specifically revised to add detailed relabeling (contraetiquetado) provisions. See Elements 4 and 7.
  • NOM-240-SSA1-2012 — governs tecnovigilancia (post-market adverse-event surveillance and reporting).
  • Acuerdo de Equivalencia con la FDA y Health Canada (DOF, October 26, 2010) and Acuerdo de Equivalencia con Japón (Ministry of Health, Labour and Welfare / PMDA; DOF, January 25, 2012) — the legacy formal equivalency instruments; see Element 8.
  • Acuerdo por el que se establece la Vía Regulatoria Abreviada (DOF, July 18, 2025; effective September 1, 2025) — the new reliance pathway referencing IMDRF Management Committee authorities and MDSAP-certified GMP; see Element 8.
  • Acuerdo que actualiza los listados de dispositivos médicos de bajo riesgo (DOF, July 7, 2025) — re-cuts the low-risk device universe into three annexes (registration-required, registration-exempt, not-a-medical-device); see Element 1.
  • Terceros Autorizados framework under the Ley General de Salud's auxiliary-control-third-party provisions — the currently published general list names 202 authorized third parties across all COFEPRIS product categories, of which 15 are specifically accredited to pre-issue technical opinions on medicine and medical-device registrations, and a further 15 to verify Good Manufacturing Practices; see Element 8.
  • 【已修正】The prior version of this page cited "Acuerdo de clasificación de dispositivos médicos" as a freestanding instrument; classification is governed directly by RIS Article 83, refined in practice by the periodically updated low-risk device-list Acuerdos (most recently July 2025) rather than by a single standalone classification agreement.

Element 1 — Device Classification and Pathway Branching

Classification is the fork that determines whether a device needs only a notification (Aviso) or a full technical review (Registro Sanitario) — and, since July 2025, a third possible outcome: no COFEPRIS filing at all. Under RIS Article 83, COFEPRIS classifies devices by the risk their use implies, in three tiers.

The 2025 low-risk re-cut adds a real fourth outcome below Class I. The July 7, 2025 Acuerdo split the low-risk universe into three explicit annexes, and this is a genuine, actionable branching decision that the classification table above does not by itself capture:

A three-year transition/grace period was granted for products that had previously operated under a case-specific COFEPRIS exception to obtain the now-applicable formal registration or exemption status.

Branching logic in practice: the real classification decision for a foreign manufacturer entering Mexico today is two-layered — first, confirm whether the device is even inside RIS scope (Annex 3 removes an unexpectedly long list of borderline products entirely); second, if it is a medical device, confirm whether it sits in Annex 1 (still registers, but as a low-risk product), Annex 2 (registration-exempt but not obligation-free), or the general Class I/II/III scheme under Article 83. Misreading a Class II device as Class I to avoid the full Registro Sanitario timeline is the most consequential and most commonly cited early-stage error, because COFEPRIS reclassification during formal review resets much of the review clock. IVDs and SaMD are classified under the same Article 83 risk logic — see the dedicated sections below.

Element 2 — License-Holder Logic: Legal Representative and Registration Ownership

This is the decision that shapes commercial control in Mexico more than any other single choice on this page, and Mexico's model is structurally more flexible than most Latin American peers — genuinely closer to a hybrid of the EU's authorized-representative logic and the mandatory-local-holder model seen in Brazil, rather than a strict copy of either.

• A Mexico-based legal representative holding a COFEPRIS Licencia Sanitaria is mandatory on every filing — no exception. The Licencia Sanitaria must cover the applicable device import/commercialization scope, and the entity must designate a Responsable Sanitario (a health officer, typically holding a relevant professional degree).
• Unlike Brazil's BRH model, the Registro Sanitario itself can be held in the manufacturer's own name, with the Mexican entity acting purely as legal representative — or it can be held in the local importer's name, with the manufacturer as a named but non-titular party. Which structure applies is determined by how the application is filed, not by law alone, which is exactly why this is a decision-grade choice rather than an administrative formality.

• Cambio de Titular (registration-holder transfer) — the single most consequential structural fact in this section. Switching the Titular of an existing Registro Sanitario requires a formal Cambio de Titular filing, which the old version of this page correctly flagged as taking approximately 3–6 months — and, as with Brazil's Alteração de Titular and Argentina's Transferencia de Titularidad, the process runs more smoothly when the outgoing holder cooperates than when the relationship ended on bad terms. Structuring which party will be Titular — and negotiating transfer-cooperation language into the distribution agreement — before the first Registro Sanitario filing is materially cheaper than renegotiating it after a distributor relationship sours.
• Practical structuring guidance: because Mexico is one of the few Latin American markets where the manufacturer can realistically retain Titular status without incorporating locally, manufacturers planning a multi-market Mexico strategy should weight the manufacturer-as-Titular-with-legal-representative model more heavily than the reflexive default of bundling registration ownership into the first distributor relationship signed — the reflexive default is faster to close, but it recreates the same lock-in risk seen across the rest of the region for no structural necessity in Mexico's specific framework.

Element 3 — Registration Validity and Review-Timeline Ranges

Why official targets and real-world figures diverge: the 60/120/180-business-day targets in RIS are administrative benchmarks, not guarantees — COFEPRIS's own documented backlog of 5,280 pending device registrations as of May 2024 means Requerimiento-round pacing and reviewer queue depth, not the nominal target, is what actually determines a Class II/III filing's real timeline. The two 2025–2026 reforms that most directly address this gap operate on different levers: the Vía Regulatoria Abreviada shortens the formal target for qualifying devices, while Terceros Autorizados reduce the practical deficiency-letter cycle for any device, qualifying or not, by moving technical completeness-checking outside COFEPRIS's own queue. A filing strategy that ignores both and simply targets the standard Registro Sanitario track is leaving real, currently available acceleration on the table.

Element 4 — In-Country Holder Obligations

Holding a Registro Sanitario or Aviso is not a one-time compliance event. The legal representative/Titular carries continuing operational duties for as long as the product remains on the Mexican market.

Practically, the legal representative/Titular's regulatory-affairs quality materially affects Requerimiento-response speed, tecnovigilancia reporting discipline, and — for Class III devices — the eventual Prórroga file's completeness. A foreign manufacturer that treats the local-representative relationship as a low-stakes administrative formality is under-pricing the risk of a mishandled Requerimiento round or a missed tecnovigilancia deadline.

Element 5 — Fee Model: Government Derecho vs. Tercero Autorizado Cost

Mexico's fee structure has two genuinely separate layers that are easy to conflate: the COFEPRIS government fee (derecho), set under the Ley Federal de Derechos and scaling with device class, and the Tercero Autorizado pre-review fee, a private-sector cost paid to an accredited third party — the second does not replace the first; a manufacturer routing through a Tercero Autorizado pays both.

The Tercero Autorizado economics, in plain terms: a manufacturer pays the government derecho regardless of which review track it uses. Routing the technical dossier through one of the 15 currently accredited Tercero Autorizado units for medicine/device registration opinions adds a private-sector fee on top — but the trade is between a known, bounded additional cost and an unbounded queue-depth risk inside COFEPRIS's own backlog. For a Class II/III filing on a tight commercial timeline, this is frequently the highest-leverage discretionary spend on the entire page.

Element 6 — Registration Forms: Aviso, Registro Sanitario, and the Post-2025 Unified Procedure

The July 2025 consolidation is a genuine simplification, not just a relabeling exercise: medical device Registro Sanitario, which previously ran through three separate procedural modalities, is now processed as a single unified procedure, with the same consolidation applied to extensions (Prórroga), permits, and alphanumeric-code assignments. Combined with the elimination of mandatory physical/paper submission for a range of supporting documents (ambulance data, sanitario-representative information, applicant details), this materially reduces the administrative friction of filing relative to the pre-2025 process — independent of, and additive to, the class-based review-timeline targets in Element 3.

Element 7 — Special Requirements

Spanish-Language Labeling Under NOM-137-SSA1-2025 (New Standard, 2026)

This is one of the largest Mexico-specific compliance workstreams on this page, and — because the new standard has a phased transition — it needs planning on two different timelines depending on when a device is already on the market versus newly entering.

• Spanish is mandatory on every label, package insert, and instructions for use. NOM-137-SSA1-2025 replaces the 2008 standard after roughly seventeen years, substantially restructuring content, definitions, and labeling requirements to align with IMDRF international labeling guidance — a direct translation of an FDA or CE label built to the old 2008 element set is not automatically sufficient under the new standard.
• Effective date and transition: the new standard enters into force 360 calendar days after its DOF publication date of May 19, 2026 (i.e., roughly May 2027), with a further 180-day allowance to exhaust existing inventory already labeled under the 2008 standard. Manufacturers preparing a Mexico launch dossier now should build to the 2025 standard directly rather than to the outgoing 2008 version, to avoid a relabeling cycle immediately after entry.

GMP Under NOM-241-SSA1-2025 (New Standard, 2025)

• Published in the DOF on April 4, 2025, replacing the prior NOM-241, and already in force — this is the currently operative GMP standard, distinct from the still-pending NOM-137 labeling update.
• Establishes minimum requirements for design, development, manufacturing, storage, and distribution of medical devices, scaled to device risk level, and newly integrates digital-health principles, risk-management requirements, and international harmonization language not present in the prior version.
• Chapter 18 was specifically revised to add detailed relabeling (contraetiquetado) provisions — new sub-clauses (18.5.2.4, 18.7.1.8, 18.7.1.9, and 18.8.3) — directly relevant to importers who relabel foreign-sourced product for the Mexican market rather than receiving it pre-labeled.
• COFEPRIS has published a companion Preguntas y Respuestas (Q&A) guide to support interpretation, aimed at manufacturers, distributors, and warehouse operators.

CENAM Local Testing

• Certain device categories — measurement-related and radiation-related devices specifically — require metrological calibration or testing at CENAM (Centro Nacional de Metrología)-accredited laboratories, independent of the core Registro Sanitario technical review.

Radioactive Devices

• Devices emitting ionizing radiation require additional licensing from CNSNS (Comisión Nacional de Seguridad Nuclear y Salvaguardias), independent of the COFEPRIS Registro Sanitario process.

USMCA Tariff Treatment

• Products with a valid USMCA Certificate of Origin (US/Canada-origin) qualify for tariff preferences; non-USMCA-origin products face import duties in the approximate 15–20% range — see Import and Customs Requirements below.

Element 8 — Shortcut Pathways: Terceros Autorizados, Acuerdos de Equivalencia, and the Vía Regulatoria Abreviada

This is the deepest section on this page, reflecting Mexico's specific and genuinely differentiated acceleration architecture — a private pre-review layer that operates independent of foreign-approval status, layered against two distinct, non-identical reference-market reliance mechanisms.

Terceros Autorizados: how the pre-review actually works

• What they are: a Tercero Autorizado is a person or entity formally authorized by COFEPRIS as an auxiliary of sanitary control — empowered to issue technical opinions on compliance with applicable requirements, ahead of COFEPRIS's own formal review. This is not a private substitute for COFEPRIS approval; it is a pre-screening layer whose favorable opinion COFEPRIS then reviews and, in the ordinary course, ratifies.
• Current authorized-reviewer landscape: the published general list of Terceros Autorizados currently names 202 authorized entities across all COFEPRIS product categories. Of these, 15 are specifically accredited to pre-issue technical opinions on medicine and medical-device registrations (new registrations, extensions, and modifications), and a separate 15 are accredited to verify Good Manufacturing Practices. This is a materially smaller pool than the 113 entities accredited for water/food/beverage quality-standard verification — a reflection of the higher technical bar for device-registration pre-review specifically.
• What they review: document/dossier completeness and technical compliance for Clase I, II, and III device registrations, and for administrative/technical modifications and extensions to existing registrations.
• How this actually speeds things up: a Tercero Autorizado's favorable technical opinion does not bypass COFEPRIS's own formal timeline target — the 60/120/180-business-day figures in Element 3 remain the nominal benchmark either way. What it changes is document-quality risk timing: technical gaps that would otherwise surface as a Requerimiento/Prevención deficiency letter mid-review (each round adding 1–6 months per Element 3) are instead caught and resolved before COFEPRIS's own clock starts running in earnest. Given COFEPRIS's documented backlog of 5,280 pending registrations as of mid-2024, front-loading this risk is a genuinely practical lever, not merely a formality.
• Practical caveat: the Tercero Autorizado list is periodically republished and individual authorizations can lapse or be revoked; confirming a specific unit's current, valid accreditation status directly with COFEPRIS before engaging it is a basic and easily-skipped diligence step.

Acuerdo de Equivalencia: the narrow, long-established route

• Scope: exactly three recognized authorities — no more. The EU (CE Mark, MDR or MDD) is not on this list, and neither is China's NMPA, under this specific legal instrument.
• What it does: COFEPRIS recognizes evaluations already conducted by these three authorities as a formal reliance basis within the standard Registro Sanitario process. Applications are still individually evaluated — "the authority that relies on decisions of other authorities remains responsible for the decisions adopted" is the operative principle — full Mexican technical documentation, biocompatibility studies, and post-market surveillance data are still required, and Spanish labeling under NOM-137-SSA1 remains mandatory.
• What it covers by device category: diagnostics, implantables, prosthetics, surgical instruments, monitoring systems, cardiovascular devices, and diagnostic tests are explicitly cited as within scope in COFEPRIS's own equivalency guidance.
• No automatic approvals or priority lists: an FDA- or Health Canada-cleared device does not skip the Registro Sanitario process; it enters the process with a stronger evidentiary basis.

September 2025 NMPA regulatory-equivalence update

Historically, NMPA was not included in the 2010/2012 three-authority Acuerdo de Equivalencia. From September 2025, however, an industry report says Mexico's regulatory-equivalence agreement formally recognizes NMPA marketing authorizations. The reported review targets are risk-class specific:

Source tier and verification status: industry report relaying an official action; checked 2026-08-18. The official instrument number and original text have not been directly verified and are queued for the monthly review. This dated update replaces the older absolute claim that NMPA had no recognized Mexican reliance value, but it does not establish automatic approval or waive local requirements.

Vía Regulatoria Abreviada: the new, broader, formally timed route (2025)

• Legal basis: published in the DOF on July 18, 2025; entered into force September 1, 2025.
• Reference authorities for medical devices: IMDRF Management Committee member countries/authorities for the technical review basis, and MDSAP-certified manufacturing sites specifically for GMP evidence — a materially broader authority set than the three-country Acuerdo de Equivalencia, at least on paper. 【待核验：NMPA recognition under the September 2025 regulatory-equivalence agreement is supported by an industry report relaying an official action (checked 2026-08-18), but the official instrument number, original text, and whether that recognition maps directly onto this separately described Vía Regulatoria Abreviada remain pending direct verification. The complete official enumeration of IMDRF reference authorities, including CE treatment, also remains pending.】
• What qualifies: only "ordinary" approvals — standard, full-review clearances from the reference authority. Accelerated approvals, conditional approvals, emergency-use authorizations, and approvals issued under judicial order are explicitly excluded.
• The identity requirement: the device seeking Mexican registration must demonstrate "características básicas esenciales idénticas" (identical essential characteristics) — matching product features, quality studies, and safety/efficacy/performance data — to the version already approved by the reference authority. A device with meaningful design, indication, or manufacturing-site differences from its reference-market version does not qualify, regardless of how strong the underlying foreign approval is.
• Dossier format: built to IMDRF Table-of-Contents guidelines for devices (the medications track separately requires ICH CTD format) — a genuine document-preparation efficiency for manufacturers whose FDA/EU/other technical files are already IMDRF-STED-aligned.
• Timeline: a formal 30-business-day target for medical devices — the single fastest formally published review-time commitment on this page, dramatically faster than the 120–180-business-day standard Class II/III targets.
• A separate, combined COFEPRIS guidance document ("Guía de Requisitos para el Trámite de Registro Sanitario de Dispositivos Médicos mediante Acuerdos de Equivalencia y Vía Regulatoria Abreviada," most recently updated mid-2026) now covers both the legacy equivalency route and the new abbreviated pathway side by side, reflecting COFEPRIS's own framing of these as related but procedurally distinct instruments.

Quick Assessment: What FDA/CE/NMPA Approval Actually Unlocks

What Neither Mechanism Waives

• No waiver of the Mexican legal representative / Licencia Sanitaria requirement — every device, regardless of reference-market approval status, still needs a Mexico-based legal representative named on the filing.
• No waiver of Spanish-language labeling under NOM-137-SSA1-2025, GMP conformity under NOM-241-SSA1-2025, or CENAM testing where an applicable NOM requires it.
• No automatic classification mapping — an FDA Class II (510(k)) device does not automatically land in Clase II under RIS Article 83; COFEPRIS makes an independent classification determination.
• No waiver of tecnovigilancia, recall, or post-market inspection obligations under either mechanism.

Practical Recommendations

1. For manufacturers with FDA, Health Canada, or Japan MHLW/PMDA clearance: actively confirm eligibility for both the Acuerdo de Equivalencia and the newer Vía Regulatoria Abreviada at filing — the two routes are not identical, and the Vía Abreviada's 30-business-day formal target is the faster commitment where the "ordinary approval" and "identical essential characteristics" tests are both met.
2. For manufacturers with CE Mark only: do not assume automatic Vía Regulatoria Abreviada eligibility on the strength of CE alone until the specific reference-authority list is confirmed directly with COFEPRIS; budget the standard Class II/III timeline as the base case, while still leveraging CE technical documentation's IMDRF-STED-adjacent structure as a document-preparation efficiency within the standard track.
3. For manufacturers with NMPA only: screen the September 2025 NMPA equivalence route first and plan around the reported Class I/II/III targets of 20/25/35 business days, while keeping the standard Registro Sanitario pathway as the fallback until the official instrument is directly verified. A Tercero Autorizado remains an independent pre-review lever regardless of foreign-approval status. Source tier and verification status are stated in the NMPA subsection above.
4. Regardless of reference-market status, evaluate the Tercero Autorizado route independently — it is the one acceleration lever on this page that does not depend on which foreign regulator has already cleared the device, and it directly addresses COFEPRIS's own documented backlog rather than working around it.
5. Do not conflate the two reference-market mechanisms in internal planning documents. The Acuerdo de Equivalencia is a 2010–2012-era, three-country instrument with no formal timeline commitment; the Vía Regulatoria Abreviada is a 2025-era, broader-authority instrument with a formal 30-business-day target but stricter "ordinary approval" and "identical characteristics" eligibility tests. Confirm which one actually applies to a specific device before quoting a timeline internally.

IVD-Specific Requirements

SaMD, AI, and Digital Health Requirements

• Legal status since July 2023: autonomous software meeting the medical-device definition — software that performs a diagnostic, therapeutic, or monitoring function independently, rather than as an accessory to a physical device — has been regulated by COFEPRIS as an active medical device since a July 2023 definitional update expanded the framework beyond software-as-accessory treatment.
• First SaMD approval — a concrete, dateable milestone: COFEPRIS officially announced its first Software as a Medical Device authorization in May 2024, approved specifically through an equivalence procedure — i.e., via the Acuerdo de Equivalencia mechanism described in Element 8, not a SaMD-specific fast track. This is a genuinely useful data point for foreign SaMD developers: it confirms the equivalency route is operationally usable for software, not merely a theoretical option on paper.
• No dedicated SaMD-specific NOM standard yet. COFEPRIS applies the Ley General de Salud, the RIS, and the existing device-focused NOMs (NOM-241-SSA1-2025 for GMP-equivalent quality processes, NOM-137-SSA1-2025 for labeling once in force) to SaMD, rather than maintaining a freestanding SaMD-specific regulation comparable to Brazil's RDC 657/2022.
• A dedicated working group exists but has not yet produced a standalone standard. COFEPRIS has convened a Working Group on Innovative Regulation addressing SaMD specifically, indicating the framework is under active development — manufacturers of adaptive/AI-driven SaMD should confirm current consultation status directly with COFEPRIS rather than assuming the present general-framework approach is final. 【待核验：SaMD/AI 专项工作组的最新进展与是否已产出正式技术指南或专项 NOM 草案，本轮未能确认】
• Practical implication: classification (Clase I/II/III under Article 83) determines the pathway exactly as it would for hardware — foreign SaMD/DTx developers should confirm classification early, and treat the May 2024 equivalence-route precedent as a viable planning basis if the product already holds FDA, Health Canada, or Japan MHLW/PMDA clearance.

Registration Dossier Requirements

• ISO 13485 certificate (current).
• Free Sale Certificate (FSC), processed through the notarization + Apostille (Hague Convention states) or consular legalization (non-member states) authentication chain.
• Product technical description (in Spanish), including intended use, indications, and contraindications.
• Risk management summary (ISO 14971-aligned, Spanish).
• Clinical/performance evidence — mandatory for Clase III; scaled as appropriate for Clase II; CE/FDA/reference-authority clinical data is generally acceptable as supporting evidence, and formally strengthened where the Acuerdo de Equivalencia or Vía Regulatoria Abreviada applies.
• Instructions for Use / labeling, in Spanish, compliant with NOM-137-SSA1 (2008 standard during the current transition window; 2025 standard once in force) and RIS requirements.
• Test reports — biocompatibility, electrical safety, and other applicable standards.
• GMP documentation, issued by the manufacturer's home-country authority or represented via ISO 13485/MDSAP evidence, authenticated per the chain above.
• Copy of the legal representative/importer's Licencia Sanitaria.
• Manufacturer's power of attorney (Carta Poder / Poder Notarial) authorizing the Mexican legal representative, notarized and authenticated.
• Packaging/sterility validation documentation, where applicable.
• Software documentation, where applicable, cross-referenced against the SaMD section above.
• IVD-specific additions: performance evaluation data and reference-interval studies.
• For the Acuerdo de Equivalencia or Vía Regulatoria Abreviada routes specifically: the qualifying foreign approval document (FDA/Health Canada/Japan for equivalencia; the applicable IMDRF-referenced authority approval for the abbreviated route), authenticated, plus — for the abbreviated route — documentation demonstrating "identical essential characteristics" between the reference-market and Mexican-market product versions.

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Tecnovigilancia (adverse-event reporting), governed by NOM-240-SSA1-2012:
  • Serious adverse events: initial report within 7 business days of awareness; final report within 30 business days.
  • Submitted through the COFEPRIS system.
  • Both the legal representative/importer and the manufacturer carry reporting obligations.
• Recall rules: a recall plan must be submitted to COFEPRIS; recalls are classified Type I / II / III; Type I recalls require public notice in major Mexican media.
• Periodic safety reports: Clase III devices must submit annual safety update reports.
• COFEPRIS market surveillance: periodic and unannounced market inspections verify ongoing compliance of products in circulation, including devices registered under Annex 1 low-risk status and those exempted under Annex 2 — exemption from registration is not exemption from surveillance.

Import and Customs Requirements

• Import authorization: each shipment of a registered device requires an Aviso de Importación or Permiso de Importación, processed through the VUCEM system (Ventanilla Única de Comercio Exterior Mexicano), contingent on a valid Registro Sanitario or Licencia Sanitaria.
• Annex 2 low-risk devices: the formal import-authorization permit is replaced by a customs declaration certifying compliance — a genuine procedural simplification, though not a compliance waiver (see Element 4).
• Customs requirements:
  • Products with a valid USMCA Certificate of Origin (US/Canada-origin) qualify for tariff preferences; non-USMCA-origin products face import duties of approximately 15–20%.
  • IVA (VAT) at 16% applies to most medical device imports.
  • Required documents: commercial invoice, packing list, certificate of origin.
  • Some devices require a COFEPRIS customs-release permit.
• Labeling language: Spanish is mandatory — see Element 7 for the full required-element framework under NOM-137-SSA1-2025, and the transition timeline from the 2008 standard.
• Common pitfalls: Apostille documents have a limited practical shelf life — confirm validity at the time of submission, not at the time of issuance. Consular-legalized documents (for non-Hague-Convention countries) are sometimes rejected by COFEPRIS on format grounds; verify current format requirements in advance rather than assuming continuity with prior submissions.

Market Access Channels

Registration is the compliance entry point, not the commercial one — obtaining a Registro Sanitario does not equal IMSS/ISSSTE procurement listing, private-hospital adoption, or patient affordability, and channel strategy should be planned in parallel with the regulatory filing.

• IMSS procurement: the nation's largest public healthcare purchaser, with annual procurement on the order of USD 2–3 billion; tendered through the CompraNet system; local registration is required; payment cycles of 60–120 days; centralized procurement has intensified in recent years, with strong price competition.
• ISSSTE procurement: the government-employee healthcare system; procurement volume second only to IMSS; broadly similar processes.
• IMSS-Bienestar: covers the previously uninsured population (successor to Seguro Popular/Insabi); budget pressure has been a recurring feature of this channel.
• Private hospitals/clinics: approximately 35% of the market; hospital chains such as ABC, Ángeles, and STAR Médica run centralized procurement, with comparatively flexible pricing — commonly the recommended initial entry point ahead of the slower public-tender cycle.
• E-commerce/distribution: low-risk consumables and home medical devices move through distributor networks (e.g., AMEDICI-affiliated channels); online-sales-specific regulation continues to tighten.
• National procurement consolidation: the 2019–2024 push toward centralized procurement, including purchases channeled through UNOPS for a portion of the consolidated medicines/supplies tender program, materially affected traditional distributor models; UNOPS-era tenders reported approximately 91% fulfillment (576 of 634 tendered items supplied) across the program's run, and the practical effect on distributor relationships and channel sequencing should be confirmed against current policy direction under the Sheinbaum administration (post-2024) rather than assumed static.

Main Players and Channel Map

Market Entry Strategy and Key Risks

• Confirm which of the three RIS annexes a low-risk device sits in before quoting a timeline. Since July 2025, "low risk" no longer implies a single outcome — Annex 1 devices still register, Annex 2 devices skip registration but not compliance, and Annex 3 devices skip the RIS framework entirely; resolve this before finalizing dossier scope.
• Decide the Titular structure deliberately, not by default. Because Mexico — unlike Brazil — genuinely allows the manufacturer itself to hold the Registro Sanitario with a Mexican legal representative attached, defaulting to a distributor-held registration surrenders more control than the legal framework actually requires; make this choice before signing any distribution agreement.
• Treat Terceros Autorizados and the equivalency/abbreviated routes as separate, stackable levers, not alternatives. A manufacturer with FDA clearance can use the Vía Regulatoria Abreviada's 30-business-day target and route the dossier through a Tercero Autorizado for pre-review — the two mechanisms address different bottlenecks (formal review scope vs. deficiency-letter cycle time) and are not mutually exclusive.
• Plan for the NOM-137-SSA1-2025 labeling transition now, even though it doesn't take effect until roughly May 2027. Building a Mexico launch dossier to the outgoing 2008 labeling standard risks a relabeling cycle immediately after the new standard's 360-day-plus-180-day transition window closes; build to the 2025 IMDRF-aligned standard directly.
• Key risks:
  • Backlog risk: COFEPRIS's documented 5,280-registration backlog (as of mid-2024) means the official 60/120/180-business-day targets should be treated as floors, not realistic estimates, for a standard-track Class II/III filing without either acceleration lever engaged.
  • Titular lock-in risk: a distributor-held Registro Sanitario that the manufacturer did not need to concede, structurally, given Mexico's more flexible framework — Cambio de Titular still takes approximately 3–6 months if the relationship sours.
  • Reform-conflation risk: treating the Acuerdo de Equivalencia and the Vía Regulatoria Abreviada as the same mechanism, when they differ in recognized authorities, formal timeline commitment, and eligibility tests.
  • Document-authentication risk: Apostille format issues and translator-qualification problems remain the most commonly cited grounds for formal-screening rejection.
  • Reform-transition risk: the April 2026 RIS reform's device-specific applicability to the 10-year Prórroga term carries a genuine sourcing caveat (see Element 3) — confirm directly with COFEPRIS or current local counsel before budgeting a 10-year renewal cycle into a long-term Mexico plan.
• Practical tips:
  • Engage a Mexican regulatory consultant with current, post-2025-reform experience specifically — pre-2025 playbooks understate what the Vía Regulatoria Abreviada and the re-cut low-risk device lists now make possible, and can equally overstate the still-narrow Acuerdo de Equivalencia scope if the two are conflated.
  • Confirm a specific Tercero Autorizado's current, valid accreditation status directly with COFEPRIS before contracting, given the periodic republication of the authorized-list.
  • Monitor DIGIPRiS platform rollout status — COFEPRIS's own 2025–2026 digitalization plan runs on a six-phase timeline through December 2026, and process details (submission requirements, in-person-appointment elimination) are actively evolving alongside it.
  • For USMCA-eligible manufacturers, fully leverage tariff preferences and the FDA/Health Canada-specific routes. For NMPA holders, separately screen the September 2025 equivalence update and its reported 20/25/35-business-day class targets; do not treat the older three-authority list as the current complete picture (industry-report update checked 2026-08-18; official text pending monthly re-verification).

Frequently Asked Questions

Who regulates medical devices in Mexico?

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), a decentralized body of the Secretaría de Salud, is the sole national regulator for medical devices, IVDs, and SaMD, with authority over classification, Aviso/Registro Sanitario review, GMP and labeling standards, import authorization, and tecnovigilancia. A network of privately accredited Terceros Autorizados performs pre-review technical opinions that feed into, but do not replace, COFEPRIS's own formal decision.

What is a Tercero Autorizado, and does it replace COFEPRIS's own review?

No. A Tercero Autorizado (Authorized Third Party) is a private entity formally accredited by COFEPRIS to issue a preliminary technical opinion on a device's registration dossier — 15 such entities are currently accredited specifically for medicine/medical-device registration opinions. COFEPRIS still conducts its own formal review and issues the actual Registro Sanitario; the Tercero Autorizado's value is catching documentation gaps before COFEPRIS's own clock and backlog queue are engaged, which in practice reduces deficiency-letter (Requerimiento/Prevención) rounds. The service carries a separate, market-set fee on top of the COFEPRIS government derecho.

Does an existing FDA, CE, or NMPA approval speed up COFEPRIS registration?

It depends on the approval and mechanism. The historical Acuerdo de Equivalencia, in force since 2010–2012, named only US FDA, Health Canada, and Japan's MHLW/PMDA. From September 2025, an industry report relaying an official action says Mexico's regulatory-equivalence agreement also formally recognizes NMPA marketing authorizations, with Class I/II/III targets of 20/25/35 business days (checked 2026-08-18; official instrument number and text pending monthly re-verification). The separately described Vía Regulatoria Abreviada has a 30-business-day target and its own eligibility tests; the exact mapping between the NMPA update and that route remains pending direct official verification. CE treatment also remains pending direct confirmation. No reliance route waives the Mexican legal representative, Spanish labeling, or GMP requirements.

How long does Mexico medical device registration actually take, end to end?

Realistic ranges by pathway: weeks to ~2 months for an Aviso/Annex-1 low-risk notification; 2–4 months for a standard Clase I Registro Sanitario; 12–18 months for Clase II; 18–30 months for Clase III. The Vía Regulatoria Abreviada carries a formal 30-business-day target for qualifying devices — the fastest published commitment on this page — while a Tercero Autorizado pre-review reduces the practical Requerimiento-cycle risk for any filing, qualifying or not.

How long is a Registro Sanitario valid, and has that changed recently?

Initial validity remains 5 years, unchanged since 2005. As of an April 2026 RIS reform, both the first and subsequent Prórroga (renewal) are now granted for 10-year periods, up from the prior 5-year renewal term — though whether this specific change applies identically to medical devices as it does to medications carries a sourcing caveat this page flags explicitly (see Element 3); confirm current scope directly before budgeting a 10-year renewal cycle. Separately, the second-and-later Prórroga filing deadline moved to 150 calendar days before expiry, and Prórroga processing time was cut from 120 to 45 calendar days under a 2025 simplification measure.

Can a foreign manufacturer hold its own Registro Sanitario in Mexico, or must a local company hold it?

A foreign manufacturer can hold its own Registro Sanitario, provided a Mexico-based legal representative holding a COFEPRIS Licencia Sanitaria is named on the filing — this is structurally more flexible than Brazil's mandatory-local-holder (BRH) model. Alternatively, a local importer/distributor can hold the registration instead. Which structure applies depends on how the application is filed, making this a first-order commercial decision (see Element 2) rather than a fixed legal requirement either way.

What changed for low-risk (Class I) devices in 2025?

COFEPRIS re-cut its low-risk device universe via a July 7, 2025 Acuerdo into three explicit tiers: 93 devices that remain low-risk but still require registration (Annex 1); 104 devices now fully exempt from registration (Annex 2), though still subject to GMP and tecnovigilancia obligations; and 1,984 products removed from RIS scope entirely as not medical devices (Annex 3). A three-year transition period applies to products previously operating under a case-specific COFEPRIS exception.

What special requirements apply beyond the core Registro Sanitario process?

Two updated Mexican standards apply beyond the core process: NOM-241-SSA1-2025 (GMP, in force since April 2025, newly covering digital-health and relabeling provisions) and NOM-137-SSA1-2025 (Spanish-language labeling, published May 2026, entering into force roughly May 2027 with a 180-day sell-through allowance for existing stock). Certain measurement- and radiation-related devices additionally require CENAM testing, and radioactive devices require separate CNSNS licensing.

Official Sources and Verification Dates

• COFEPRIS — official portal: https://www.gob.mx/cofepris (accessed 2026-08-17)
• COFEPRIS — DIGIPRiS electronic filing platform: https://digipris.cofepris.gob.mx (accessed 2026-08-17)
• COFEPRIS — Terceros Autorizados program page: https://www.gob.mx/cofepris/acciones-y-programas/terceros-autorizados (accessed 2026-08-17; 202-entity general list, 15 medicine/device-registration and 15 GMP-verification accreditation counts cross-checked via COFEPRIS press release coverage)
• COFEPRIS press release — publication of the 202-entity Terceros Autorizados general list: https://www.gob.mx/cofepris/prensa/publican-lista-de-202-terceros-autorizados-como-auxiliares-de-la-cofepris-en-el-control-sanitario-de-productos-y-servicios-79847 (accessed 2026-08-17)
• Diario Oficial de la Federación — NOM-241-SSA1-2025, Buenas prácticas de fabricación de dispositivos médicos (published April 4, 2025): https://dof.gob.mx/normasOficiales/9497/salud/salud.html (accessed 2026-08-17)
• Diario Oficial de la Federación — NOM-137-SSA1-2025, Etiquetado de dispositivos médicos (published May 19, 2026): https://www.dof.gob.mx/normasOficiales/9557/salud/salud.html (accessed 2026-08-17)
• Greenberg Traurig LLP — "Publicación de acciones de simplificación y listados de dispositivos médicos" (July 2025 low-risk device list annexes, procedure consolidation): https://www.gtlaw.com/en/insights/2025/7/publicacion-de-acciones-de-simplificacion-y-listados (accessed 2026-08-17)
• Greenberg Traurig LLP — "Reformas al Reglamento de Insumos para la Salud" (April 2026 RIS reform, new molecules, Prórroga term change): https://www.gtlaw.com/en/insights/2026/5/reformas-al-reglamento-de-insumos-para-la-salud (accessed 2026-08-17)
• Basham, Ringe y Correa — "Reformas clave a los Reglamentos de Insumos para la Salud y de Registros, Importación y Exportación de Sustancias Reguladas" (April 2026 RIS reform, Prórroga extended to 10 years, 150-day filing deadline): https://basham.com.mx/reformas-clave-a-los-reglamentos-de-insumos-para-la-salud-y-de-registros-importacion-y-exportacion-de-sustancias-reguladas/ (accessed 2026-08-17)
• AAMovers — "Guía COFEPRIS: Registro sanitario de dispositivos médicos por Acuerdos de Equivalencia y Vía Abreviada" (2026 combined guidance bulletin, MSI-BI-76-26): https://www.aamsimx.com/guia-registro-sanitario-dispositivos-medicos-equivalencia-via-abreviada-cofepris-2026/ (accessed 2026-08-17)
• ANCE Salud — "Nueva Vía Regulatoria Abreviada de COFEPRIS: Transformando el Registro de Medicamentos y Dispositivos Médicos en México" (legal basis, effective date, IMDRF/MDSAP reference authorities, 30/45-business-day targets, "identical essential characteristics" and "ordinary approval" eligibility tests): https://salud.ance-connect.org/nueva-via-regulatoria-abreviada-de-cofepris-transformando-el-registro-de-medicamentos-y-dispositivos-medicos-en-mexico/ (accessed 2026-08-17)
• Milenio — "Cofepris avala dispositivos médicos de Canadá, Japón y FDA para agilizar su llegada a México" (Acuerdo de Equivalencia dates and scope: FDA/Health Canada October 26, 2010; Japan January 25, 2012): https://www.milenio.com/ciencia-y-salud/cofepris-busca-agilizar-dispositivos-medicos-de-japon-y-canada (accessed 2026-08-17)
• bioaccess — "Navigate COFEPRIS Equivalency Routes for Canada and FDA Success" (equivalency-route documentation requirements): https://bioaccessla.com/blog/navigate-cofepris-equivalency-routes-for-canada-and-fda-success (accessed 2026-08-17)
• MedEnvoy Global — "COFEPRIS Publishes New Guidance on Medical Device Registration via Equivalence and Abbreviated Pathways" (June 2026 guidance document details, IMDRF cross-reference requirements): https://medenvoyglobal.com/blog/cofepris-publishes-new-guidance-on-medical-device-registration-via-equivalence-and-abbreviated-pathways/ (accessed 2026-08-17)
• El Financiero — "Cofepris mantiene rezago de 5,280 registros sanitarios de dispositivos médicos" (May 2024 backlog figure): https://www.elfinanciero.com.mx/empresas/2024/05/07/cofepris-mantiene-rezago-de-5280-registros-sanitarios-de-dispositivos-medicos/ (accessed 2026-08-17)
• El Financiero — "Digitalización de Cofepris: inversión estratégica en un momento decisivo" (DIGIPRiS six-phase 2025-2026 modernization plan, budget): https://www.elfinanciero.com.mx/opinion/colaborador-invitado/2026/05/06/digitalizacion-de-cofepris-inversion/ (accessed 2026-08-17)
• Thema Med — "México: primeras autorizaciones de Software como Dispositivo Médico (SaMD) innovador" (May 2024 first SaMD approval via equivalence procedure): http://www.thema-med.com/es/2024/06/21/messico-prime-autorizzazioni-di-innovativi-software-as-a-medical-device-samd/ (accessed 2026-08-17)
• Salud Digital — "La regulación de software y aplicaciones médicas y los avances de la COFEPRIS en México" (SaMD July 2023 definitional update, Working Group on Innovative Regulation): https://saluddigital.com/big-data/la-regulacion-de-software-y-aplicaciones-medicas-y-los-avances-de-la-cofepris-en-mexico/ (accessed 2026-08-17)
• adn40 — "Esto dice la guía de Cofepris sobre el registro de medicamentos y dispositivos médicos" (device Registro Sanitario 5-year initial validity since 2005, DIGIPRiS filing) and ANCE Salud — "Registro de dispositivos médicos ante COFEPRIS" (60/120/180-business-day per-class review targets): https://www.adn40.mx/salud/cofepris-publica-guia-registro-medicamentos-dispositivos-medicos, https://salud.ance-connect.org/registro-de-dispositivos-medicos-ante-cofepris/ (accessed 2026-08-17)
• consultorsalud — "Registro de dispositivos médicos en México: nueva guía Cofepris" and "COFEPRIS: 11 trámites con exención de pago en 2026" (2026 derecho fee reference points): https://consultorsalud.com.mx/cofepris-via-abreviada-dispositivos-medicos/, https://consultorsalud.com.mx/cofepris-exenciones-pago-tramites-sector/ (accessed 2026-08-17)
• La Razón — "UNOPS otra vez se queda corta en compra de medicinas" (UNOPS-era consolidated procurement fulfillment rate): https://www.razon.com.mx/mexico/unops-vez-queda-corta-compra-medicinas-484427 (accessed 2026-08-17)
• Verification date: 2026-08-17

Items Flagged for Further Verification (【待核验】)

• Whether the April 2026 RIS reform's extension of the Prórroga (renewal) term from 5 to 10 years applies identically to medical devices as it does to medications — one secondary source explicitly states the change covers "medicamentos y dispositivos médicos," while a second, more detailed analysis of the same reform focuses exclusively on medication-specific provisions (new molecules, patent-term compensation, data protection) without independently confirming the device-specific renewal-term language. Confirm directly against the RIS's April 2026 amended text before relying on the 10-year figure for device renewal planning.
• The complete, enumerated list of IMDRF Management Committee reference authorities COFEPRIS recognizes under the Vía Regulatoria Abreviada for medical devices — no source fetched this pass provided a country-by-country enumeration, and in particular whether the EU and/or China's NMPA fall within this authority set (as distinct from the narrower, explicitly three-country Acuerdo de Equivalencia) could not be independently confirmed. Verify directly against COFEPRIS's official "Guía de Requisitos" document before assuming CE or NMPA eligibility.
• The official instrument number and original text for the NMPA recognition reported as effective from September 2025. The recognition itself and the Class I/II/III targets of 20/25/35 business days are supported here only by an industry report relaying an official action, checked 2026-08-18; direct official verification is queued for the monthly review. Also confirm whether this NMPA equivalence route is legally identical to, nested within, or separate from the page's Vía Regulatoria Abreviada description.
• Exact current COFEPRIS derecho (government fee) amounts by device class under the applicable Ley Federal de Derechos schedule — the MXN/USD figures in the Quick Reference and Element 5 combine figures carried over from the prior version of this page with a small number of independently confirmed 2026 reference points (the MXN 12,379.32 research-protocol fee and the MXN 164,122.92 manufacturing-plant fee); the full class-by-class Registro Sanitario fee table was not exhaustively verified line-by-line against the current official schedule.
• Whether a formally published, official acceleration timeline (in business days) exists for the Acuerdo de Equivalencia route specifically, distinct from the newer Vía Regulatoria Abreviada's confirmed 30-business-day target — no official COFEPRIS-published figure was located for the equivalencia route itself this pass; treat any specific day-count cited for it as directional, not contractual.
• Whether a dedicated, standalone regulatory instrument for IVD classification (comparable to Brazil's RDC 830/2023) exists in Mexico, or whether IVDs remain fully integrated into the general RIS Article 83 framework without a separate codified track — this page presents the latter based on available sourcing but flags it as not independently and exhaustively confirmed.